For instance, Dalfampridine is a KCNQ5 inhibitor that has been approved to improve mobility in multiple sclerosis patients, and KCNQ5 inhibitors [25] have been explored also for other neurological conditions including amyotrophic lateral sclerosis, Gullian-Barre Syndrome, unipolar depression and cerebral palsy (Open Target annotations). Here, KCNQ5 is linked to multiple sclerosis.